Josson et al. first demonstrates the inhibition of ADAM9 enhances the sensitivity to numerous common chemotherapy drugs (including doxorubicin, cisplatin, and gemcitabine) in prostate cancer cells [110]. The gene discussed is ADAM9; the disease is prostate carcinoma.